This Article Full Text Full Text (PDF) All Versions of this Article: chest.07-0996v1 133/3/767    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schenkein, J. G. Articles by Dransfield, M. T. Search for Related Content PubMed PubMed Citation Articles by Schenkein, J. G. Articles by Dransfield, M. T. Related Content Special Features

Pneumococcal Vaccination for Patients With COPD^*

Current Practice and Future Directions

^* From The University of Alabama at Birmingham, Birmingham, AL.

Correspondence to: Mark Dransfield, MD, 422 THT 1900 University Blvd, Birmingham, AL 35294; e-mail: mdransfield99{at}msn.com

Abstract

Despite a level "A" recommendation by the Centers for Disease Control and Prevention, the use of pneumococcal polysaccharide vaccination in patients with COPD is supported by limited data. Clinical and laboratory studies have suggested that the currently approved vaccine is less effective in the population of COPD patients than in healthier patients, and to date no randomized-controlled trial of pneumococcal vaccination for COPD patients has demonstrated any beneficial effect. The implementation of a pneumococcal vaccine trial in the COPD population is problematic because of the large sample size required for studies examining clinical outcomes and the fact that no adequate in vitro assays have been available to serve as surrogate measures of vaccine protection. However, new laboratory methods have been developed and more accurate determination of the immunogenicity of pneumococcal vaccines is now possible. There is considerable interest in the development of an improved pneumococcal vaccine for patients with COPD, and advances in vaccine design hold considerable promise for improved prevention against pneumonia and acute exacerbations caused by Streptococcus pneumoniae. The following discussion will examine the available data supporting pneumococcal polysaccharide vaccine use, the currently available laboratory methods to measure immunogenicity, and advances in the development of an improved pneumococcal vaccine that could better protect patients with COPD against this pathogen.

Key Words: COPD • pneumonia • pneumonia vaccine